Published online 31 July 2006 doi:10.1084/jem.20051557
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 203, Number 8, 2033-2042
Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread
Lars Hangartner1,
Raphaël M. Zellweger1,
Mattia Giobbi2,
Jacqueline Weber1,
Bruno Eschli1,
Kathy D. McCoy1,
Nicola Harris1,
Mike Recher1,
Rolf M. Zinkernagel1, and
Hans Hengartner1
1 Institute of Experimental Immunology, University Hospital Zürich, 8091 Zürich, Switzerland
2 Mettler-Toledo (Schweiz) GmbH, 8606 Greifensee, Switzerland
CORRESPONDENCE Lars Hangartner: lhangart{at}scripps.edu
The biological relevance of nonneutralizing antibodies elicited early after infection with noncytopathic persistence-prone viruses is unclear. We demonstrate that cytotoxic T lymphocytedeficient TgH(KL25) mice, which are transgenic for the heavy chain of the lymphocytic choriomeningitis virus (LCMV)neutralizing monoclonal antibody KL25, mount a focused neutralizing antibody response following LCMV infection, and that this results in the emergence of neutralization escape virus variants. Further investigation revealed that some of the escape variants that arose early after infection could still bind to the selecting antibody. In contrast, no antibody binding could be detected for late isolates, indicating that binding, but nonneutralizing, antibodies exerted a selective pressure on the virus. Infection of naive TgH(KL25) mice with distinct escape viruses differing in their antibody-binding properties revealed that nonneutralizing antibodies accelerated clearance of antibody-binding virus variants in a partly complement-dependent manner. Virus variants that did not bind antibodies were not affected. We therefore conclude that nonneutralizing antibodies binding to the same antigenic site as neutralizing antibodies are biologically relevant by limiting early viral spread.
Abbreviations used: CVF, cobra venom factor; GP, glycoprotein; LCMV, lymphocytic choriomeningitis virus; MFI, mean fluorescence intensity; TAP, transporter associated with antigen processing.
L. Hangartner and R.M. Zellweger contributed equally to this work.
L. Hangartner's present address is Department of Immunology IMM-2, The Scripps Research Institute, La Jolla, CA 92037.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
-
Huber, M., von Wyl, V., Ammann, C. G., Kuster, H., Stiegler, G., Katinger, H., Weber, R., Fischer, M., Stoiber, H., Gunthard, H. F., Trkola, A.
(2008). Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked. J. Virol.
82: 3834-3842
[Abstract]
[Full Text]
-
Sugimoto, C., Nakayama, E. E., Shioda, T., Villinger, F., Ansari, A. A., Yamamoto, N., Suzuki, Y., Nagai, Y., Mori, K.
(2008). Impact of glycosylation on antigenicity of simian immunodeficiency virus SIV239: induction of rapid V1/V2-specific non-neutralizing antibody and delayed neutralizing antibody following infection with an attenuated deglycosylated mutant. J. Gen. Virol.
89: 554-566
[Abstract]
[Full Text]
-
Matter, M., Pavelic, V., Pinschewer, D. D., Mumprecht, S., Eschli, B., Giroglou, T., von Laer, D., Ochsenbein, A. F.
(2007). Decreased Tumor Surveillance after Adoptive T-Cell Therapy. Cancer Res.
67: 7467-7476
[Abstract]
[Full Text]